Appeal No. 2001-1485
Application No. 08/532,211
lines 23-27). The ACA level is lowered such that the final
product has an ACA which is acceptable immediately, without
appreciable change in the monomer content after 6 months (Column
8, lines 8-10). From the evidence provided by the appellants,
this ACA can initially be 25 (Specification, page 11, Table 1).
If one of skill in the art starts with the Neurath solvent
detergent modified ISG, and further treats that product by the
Tenold process, the ISG would apparently still have an
unacceptable ACA level. (See specification, table 3, page 12).
The examiner does not dispute the data in the specification
showing that simply treating a solvent detergent virally
inactivated ISG solution obtained by way of the Neurath process
will not have an acceptable ACA level immediately or shortly after
being further treated by the procedure described in Tenold.
Rather, the examiner relies upon the data reported after
containers of the Tenold treated ISG had been stored for six
months.
Specifically, Tenold states at column 9, lines 15-30 that
initial results indicated that a monomer level of 99% had been
achieved. That level of monomer content had been maintained for
six months. How does the Tenold data compare with the data in the
present specification? Not well.
The appellants state that they treated solvent detergent
virally inactivated ISG obtained by way of the Neurath process
9
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: November 3, 2007